Maximum quantity allowed is 999
CAS RN: 143491-57-0 | Product Number: E1007
Emtricitabine

Purity: >98.0%(T)(HPLC)
Size | Unit Price | Hyderabad | Japan* | Quantity |
---|---|---|---|---|
25MG |
₹3,900.00
|
1 | 22 |
|
250MG |
₹8,000.00
|
2 | 32 |
|
*Upon orders receipt, Hyderabad stocks will be dispatched on the same day.
*Items available in Japan warehouse will be dispatched in 10-12 working days.
*INR price is exclusive of domestic taxes applicable.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Supplemental Product Information:
This product is a sample for RUO (research use only). Do not use this product for any purpose other than testing and research.
Product Number | E1007 |
Purity / Analysis Method | >98.0%(T)(HPLC) |
Molecular Formula / Molecular Weight | C__8H__1__0FN__3O__3S = 247.24 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Room Temperature (Recommended in a cool and dark place, <15°C) |
CAS RN | 143491-57-0 |
Reaxys Registry Number | 5908714 |
PubChem Substance ID | 253660241 |
Merck Index (14) | 3565 |
MDL Number | MFCD00870151 |
Appearance | White to Light yellow powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Purity(Nonaqueous Titration) | min. 98.0 % |
Melting point | 153.0 to 157.0 °C |
Specific rotation [a]20/D | -137.0 to -143.0 deg(C=0.25, MeOH) |
Melting Point | 155 °C |
Specific Rotation | -140° (C=0.25,MeOH) |
Maximum Absorption Wavelength | 280 nm (H__2O) |
Solubility in water | Soluble |
Degree of solubility in water | 112 g/l 25 °C |
RTECS# | UW7360500 |
References
- Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
- Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
- Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus
- Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection
- Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.